VJHemOnc Podcast

The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients

The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)...

The post The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients appeared first on VJHemOnc.

Systemic mastocytosis: current landscape, novel agents and COVID-19

Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with...

The post Systemic mastocytosis: current landscape, novel agents and COVID-19 appeared first on VJHemOnc.

MRD assessment in AML: incorporation into clinical practice

Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable...

The post MRD assessment in AML: incorporation into clinical practice appeared first on VJHemOnc.

Myeloma management in the COVID-19 era

The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians...

The post Myeloma management in the COVID-19 era appeared first on VJHemOnc.

CAR-T in the CLL space

Novel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients...

The post CAR-T in the CLL space appeared first on VJHemOnc.

CAR T-cell therapy & multiple myeloma: past, present & future

CAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable...

The post CAR T-cell therapy & multiple myeloma: past, present & future appeared first on VJHemOnc.

Harnessing the tumor microenvironment in lymphoma therapy

A deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into...

The post Harnessing the tumor microenvironment in lymphoma therapy appeared first on VJHemOnc.

Induction therapy in myeloma: an ever-changing paradigm

In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only been possible with the use of high-dose therapy plus autologous stem cell transplantation. Novel agents are changing the treatment landscape, with combinations of daratumumab, dexamethasone, thalidomide, bortezomib and lenalidomide increasing the rates of complete remission and partial response compared to VAD.

In this podcast, the endless possible combinations are discussed by Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France. Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Mohty gives us his insight into induction therapy and also where we may be going next.

Precision epigenetic therapy for B-cell lymphoma

Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus, a continued need exists for the development of innovative approaches and therapies. Epigenetic dysregulation may drive and/or promote tumorigenesis in various malignancies and is prevalent in both B-cell and T-cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of patients with hematological malignancies. This podcast features Ari Melnick, MD, of the Weill Cornell Medical College, New York, NY. The footage included is from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Acute leukemia: pushing boundaries in disease management

This is an exciting time in the acute leukemia field, with advances in both the treatment landscape and the pathology of the disease. This podcast features a recent discussion amongst acute leukemia experts from the International Workshop on Acute Leukemias (iwAL) 2019 conference held in Barcelona, Spain. In this podcast, Noelle Frey, MD , University of Pennsylvania, Philadelphia, PA; Bianca Santomasso, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY; and Wendy Stock, MD, of the University of Chicago Medicine, Chicago, IL, discuss a vast range of topics, including the improvement of patient outcomes, the use of CAR T-cell therapy and the importance of MRD in prognostics.